Potassium bromide

for IR spectroscopy Uvasol®

Hydrobromic Acid Potassium Salt, Potassium bromide
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
MDL number:
EC Index Number:
Pricing and availability is not currently available.

storage conditions

Store at +5°C to +30°C.

vapor pressure

1.3 hPa ( 795 °C)

Quality Level


>2000 mg/kg LD50, oral (Rat)


5.5-8.5 (20 °C, 50 g/L in H2O)


1435 °C/1013 hPa


730 °C


650 g/L


2.75 g/cm3 at 20 °C

bulk density

900‑1000 kg/m3



InChI key


Related Categories

General description

Potassium bromide is transparent from the near UV to long wave IR wavelengths. In IR-spectroscopy, solid samples which are difficult to melt or dissolve in any suitable IR-transmitting solvent, are analyzed by grinding with Potassium bromide powder, and pressing into a disc. This procedure has a high quality demand of the used potassium bromide. Potassium bromide Uvasol is adjusted to a mean particle size of 150 μm. This is sufficient for the preparation of perfectly good pellets without the need for further pre-treatment and the associated risk of contamination. It also retains its powdery form over a period of years if stored in an air-tight condition. Its physical suitability for pelletising is checked by a special application test and its chemical purity established by full spectrum FT-IR analysis.


Replaces: PX1378

Analysis Note

Application test: passes test
Absorbance(2g pressed disk, 0.5 cm layer thickness)(Water; 3775-3050/1760-1520 cm⁻¹): ≤ 0.15
Absorbance(2g pressed disk, 0.5 cm layer thickness)(CH-compounds; 3050-2750 cm⁻¹): ≤ 0.004
Absorbance(2g pressed disk, 0.5 cm layer thickness)(other ; 4000-400 cm⁻¹): ≤ 0.020
Particle Size (d10): ≤ 100 µm
Particle Size (d50): ≤ 200 µm
Particle Size (d90): ≤ 500 µm

Legal Information

UVASOL is a registered trademark of Merck KGaA, Darmstadt, Germany


Exclamation mark

Signal Word


Hazard Statements

Precautionary Statements

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Aripiprazole is an atypical antipsychotic and a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole was first approved by the U.S. Food and DrugAdministration in November 2002 for schizophrenia and by the European Medicines Agency in June 2004 for acute manic and mixed episodes associated with bipolar disorder.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.